In previous clinical trials of single-agent PD-1/PD-L1 blockade in recurrent or metastatic cervical cancer, reported response rates have ranged from 4% (42)to 26% (43), and disease control rates (DCR) have varied from 40% (42) to 68% (43). Here, CD274 is linked to cervical cancer.